Bioidentical Hormones - U.S. Senate Special Committee on Aging
Bioidentical Hormones - U.S. Senate Special Committee on Aging Bioidentical Hormones - U.S. Senate Special Committee on Aging
131 Clinical Characteristics ONon-Hodgkin's Lymphoma 4 *Colorectal 2 *Ovarian 2 "Post BMT 1 *Lung 1 *Leukopenia 3 "No cancer + FHx, hematological 8 WP Data eAverage lennth of use: 22 years as on October 2n06 -Ranges 6 mo to 4.5 years *Blood levels and tests *Dose Adjustments -28/54 oCompliance *Drop out Wiley Protocol AE's "Pulmonary embolism -71y.o. after 3 years; cont'd WP
*Breast cancer 132 -57 y.o. recurrence resected- continued -59 y.o. new cancer opposite breast after 2 years .(present at time of Initiation) Adverse Events 60 y.o. breast cancer mass removed- no nodes taken Started WP 1 year later Axillary mass 1 years after WP Restaged- only axilla 2 nodes present at 2nd surgery Ovarian Cancer IMIc -49 y.o. 2.5 years on WP Wiley Protocol Concerns *Fibroids: for better, stable, or worse- *Endometrial thickening or cancers - 0 *Cardiac events, stroke,-or DVT -0 *Gallbladder disease -3 surgery -2
- Page 83 and 84: Statement of Loyd V. Allen, Jr., Ph
- Page 85 and 86: 82 Senator SMITH. Dr. Allen, as I h
- Page 87 and 88: 84 Now, when you are talking about
- Page 89 and 90: 86 The only thing the WHI proved wa
- Page 91 and 92: 88 Testimony Of T.S. Wiley before t
- Page 93 and 94: Confusion and Media Hype 90 Instead
- Page 95 and 96: 92 see a doctor tell a diabetic nea
- Page 97 and 98: 94 the only compelling reason to ta
- Page 99 and 100: 96 identical hormones synthesized f
- Page 101 and 102: 98 The world as we know it, from ba
- Page 103 and 104: 100 thereby experienced long period
- Page 105 and 106: 102 Bio-identical progesterone repl
- Page 107 and 108: 104 had reached optimum theoretical
- Page 109 and 110: 106 and the patient can be can reas
- Page 111 and 112: 108 Estradiol and Analytical Resear
- Page 113 and 114: 110 A controlled systematic pilot c
- Page 115 and 116: 112 of set doses. The Wiley Protoco
- Page 117 and 118: 114 I'd advocate for either Accredi
- Page 119 and 120: 116 D.C., and established a goal to
- Page 121 and 122: 118 If this legislation passes, fed
- Page 123 and 124: first and second finger on the barr
- Page 125 and 126: 122 These products that have been s
- Page 127 and 128: 124 Bcl-2, survivin and variant CD4
- Page 129 and 130: 126 These are experiments by other
- Page 131 and 132: 128 cerebro-cellular inflammation c
- Page 133: 130 Years # women *1>0.5 8 *1+ 9 *2
- Page 137 and 138: 134 *Labor intense for patient and
- Page 139 and 140: 136 Senator SMITH. Thank you very m
- Page 141 and 142: 138 makes these hormones uniquely s
- Page 143 and 144: 140 tomize the Wiley Protocol by ra
- Page 145 and 146: 142 "natural," because all lead to
- Page 147 and 148: 144 maceutical commerce, often with
- Page 149 and 150: 146 WHITE PAPER #1 DID YOU KNOW THA
- Page 151 and 152: 148 WHITE PAPER #2 Pharmacy Compoun
- Page 153 and 154: 150 bleeding of the bowel, locate t
- Page 155 and 156: 152 compounding standards can be en
- Page 157 and 158: 154 I. The FDA's definition of a "N
- Page 159 and 160: 156 ORIIGINAL CONTrMIBTION JANMA-EX
- Page 161 and 162: Initially, the design allowed women
- Page 163 and 164: ards analyses," stratified by clini
- Page 165 and 166: year). These 'drop-in" rates were a
- Page 167 and 168: years of prior use, 11 vs 2; HR, 4.
- Page 169 and 170: trogen plus progestin exposure. Clo
- Page 171 and 172: 168 RISKS AND BENEFITS OF ESTROGEN
- Page 173 and 174: EFFECTS OF POSTMENOPAUSAL ESTIROGEN
- Page 175 and 176: EFFECTS OF POSTMENOPAUSAL ESTROGEN
- Page 177 and 178: EFFECTS OF POSTMENOPAUSAL ESTROGEN
- Page 179 and 180: pEyECTS OF POSTMENOPAUSAL ESTROGEN
- Page 181 and 182: EFFECTS OF POSTMENOPAUSAL ESTROGEN
- Page 183 and 184: EFFECTS OF POSTMENOPAUSAL ESTROGEN
*Breast cancer<br />
132<br />
-57 y.o. recurrence resected- c<strong>on</strong>tinued<br />
-59 y.o. new cancer opposite breast after 2 years<br />
.(present at time of Initiati<strong>on</strong>)<br />
Adverse Events<br />
60 y.o. breast cancer mass removed- no nodes taken<br />
Started WP 1 year later<br />
Axillary mass 1 years after WP<br />
Restaged- <strong>on</strong>ly axilla 2 nodes present at 2nd surgery<br />
Ovarian Cancer IMIc<br />
-49 y.o. 2.5 years <strong>on</strong> WP<br />
Wiley Protocol C<strong>on</strong>cerns<br />
*Fibroids: for better, stable, or worse-<br />
*Endometrial thickening or cancers - 0<br />
*Cardiac events, stroke,-or DVT -0<br />
*Gallbladder disease -3 surgery -2
Change language